Quang X. Pham - Jan 23, 2025 Form 4/A - Amendment Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role: CEO and Chairman, Director, 10%+ Owner
Signature: /s/ Matthew K. Szot, Attorney-in-fact
Stock symbol: CVKD
Transactions as of: Jan 23, 2025
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 3/24/2025, 08:38 PM
Date Of Original Report: Jan 24, 2025
Previous filing: Apr 10, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CVKD	Stock Options	Award	$0	+65K		$0.00	65K	Jan 23, 2025	Common Stock	65K	$19.79	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amendment to Form 4 is being filed to correct the exercise price and the expiration date of the stock option, which were incorrectly reported on the original Form 4 filed by the Reporting Person on January 24, 2025 (the "Original Form 4"). The exercise price of the stock option is equal to 100% of the fair market value of the Issuer's common stock on the effective date of the grant and the stock option expires ten years from the date of issuance. The stock option vests according to the vesting schedule as previously reported on the Original Form 4.

Content

This amendment to Form 4 is being filed to correct the exercise price and the expiration date of the stock option, which were incorrectly reported on the original Form 4 filed by the Reporting Person on January 24, 2025 (the "Original Form 4"). The exercise price of the stock option is equal to 100% of the fair market value of the Issuer's common stock on the effective date of the grant and the stock option expires ten years from the date of issuance. The stock option vests according to the vesting schedule as previously reported on the Original Form 4.